Thanthong Saengrawee, Kotronoulas Grigorios, Johnston Bridget
School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, UK.
NHS, Greater Glasgow& Clyde, Glasgow, Scotland, UK.
Asia Pac J Oncol Nurs. 2024 Aug 22;11(10):100577. doi: 10.1016/j.apjon.2024.100577. eCollection 2024 Oct.
Palliative thoracic radiotherapy is a key treatment option for symptom management in advanced lung cancer. Continuous symptom monitoring is critical to ensuring optimal therapeutic outcomes and preserving patients' well-being. This systematic review aimed to explore patients' symptom experiences during palliative thoracic radiotherapy for advanced lung cancer.
Following PRISMA guidelines, we conducted a comprehensive search of MEDLINE, EMBASE, CINAHL, Cochrane, and PsycINFO from database inception through August 31, 2023. Eligible studies included those examining the prevalence and severity of symptoms and side effects experienced by adult patients undergoing palliative thoracic radiotherapy for advanced lung cancer, regardless of treatment duration or dosage. Methodological quality was assessed using the standardized QualSyst tool, and data were synthesized narratively.
A total of 8 studies met the inclusion criteria. Thirteen symptoms were reported prior to radiotherapy, with cough being the most common (62%). Symptom severity ranged from mild to severe, with dyspnoea recording the highest average score. Distress was not measured during this phase. Post-radiotherapy, fatigue was the most prevalent symptom (69%), followed by cough (64%) and dyspnoea (50%). Symptom severity varied across studies, with improvements noted in cough, dyspnoea, chest pain, and haemoptysis. Moderating factors influencing symptom prevalence and variation included performance status, weight loss, cancer stage, objective tumour response, and radiation-induced pulmonary changes.
Symptom control through palliative thoracic radiotherapy demonstrates variability in both frequency and severity of symptoms. Systematic monitoring is essential for identifying persistent symptoms and determining the need for more targeted supportive care interventions.
姑息性胸部放疗是晚期肺癌症状管理的关键治疗选择。持续的症状监测对于确保最佳治疗效果和维护患者的健康至关重要。本系统评价旨在探讨晚期肺癌患者在姑息性胸部放疗期间的症状体验。
遵循PRISMA指南,我们对MEDLINE、EMBASE、CINAHL、Cochrane和PsycINFO进行了全面检索,检索时间从数据库建立至2023年8月31日。符合条件的研究包括那些调查接受晚期肺癌姑息性胸部放疗的成年患者所经历症状和副作用的发生率及严重程度的研究,无论治疗持续时间或剂量如何。使用标准化的QualSyst工具评估方法学质量,并对数据进行叙述性综合分析。
共有8项研究符合纳入标准。放疗前报告了13种症状,咳嗽最为常见(62%)。症状严重程度从轻度到重度不等,呼吸困难的平均得分最高。此阶段未测量痛苦程度。放疗后,疲劳是最普遍的症状(69%),其次是咳嗽(64%)和呼吸困难(50%)。不同研究中症状严重程度各不相同,咳嗽、呼吸困难、胸痛和咯血均有改善。影响症状发生率和变化的调节因素包括体能状态、体重减轻、癌症分期、客观肿瘤反应和放射性肺改变。
通过姑息性胸部放疗进行症状控制在症状的频率和严重程度方面均表现出差异。系统监测对于识别持续症状和确定是否需要更有针对性的支持性护理干预至关重要。